Abstracts tagged "Diagnostic Tests"

Abstract Number: 101 • 2015 ACR/ARHP Annual Meeting
New Technologies for Typing Self-Identifying Antigens Encoded By HLA Genes Provide Cost-Effective Alternatives to Identifying B27 Allele Status in Rheumatoid Arthritis Subjects
Kimberly Robasky¹, Jatinder Kaur², Jennifer Sims¹, Melissa Howard¹, Eric Earley¹ and Eric Lai², ¹EA|Quintiles, Durham, NC, ²Takeda Pharmaceuticals International, Inc., Deerfield, IL
Background/Purpose: Human leukocyte antigen (HLA) genes code for proteins that allow the immune system to distinguish self from foreign cells. These genes have important indications…
Abstract Number: 2617 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3eta Protein Elevation in Osteoarthritis Suggests Misclassification or Concurrent Inflammatory Arthritis
Olga S. Zhukov¹, Jonnielyn G. Rivera¹, Rania W. Abolhosn¹, Robert J. Lagier², Charles M. Rowland³, Joanna M. Popov¹, Kaleb Michaud⁴ and Stanley J. Naides¹, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ³Research Support, Quest Diagnostics Alameda, Alameda, CA, ⁴Rheumatology & Immunology, University of Nebraska Medical Center and National Data Bank, Omaha, NE
Background/Purpose: Tissue distribution of the chaperonin 14-3-3η (eta) is limited to synovial tissue and brain. Synovium releases proinflammatory 14-3-3η into synovial fluid and serum in…
Abstract Number: 292 • 2015 ACR/ARHP Annual Meeting
Neoepitope Biomarkers As Biomarkers of Polymyositis and Dermatomyositis and Functional Status
Anders Nedergaard¹, Kim Henriksen², Morten Asser Karsdal³, Wendy White⁴ and Xiang Guo⁴, ¹Institute of Sports Medicine Copenhagen, Bispebjerg Hospital, Copenhagen NW, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Polymyositis (PM) and Dermatomyositis (DM) are inflammatory conditions characterized by persistent inflammation of muscle tissue (and for DM also skin). Myositis has been shown…
Abstract Number: 2653 • 2015 ACR/ARHP Annual Meeting
Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis
Uta Kiltz¹, Christine von Zabern¹, Xenofon Baraliakos¹, Frank Heldmann¹, Bernhard Mintrop¹, Michael Sarholz¹, Martin van Werde¹, Claudia Klink², Dietmar Krause², Friedrich Dybowski³, Ludwig Kalthoff³, Liane Hein³ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Private rheumatology office, Gladbeck, Germany, ³Private rheumatology office, Herne, Germany
Background/Purpose: In patients with tender and swollen finger joints, the differential diagnosis between rheumatoid arthritis (RA) and osteoarthritis (OA) of the hands can be initially…
Abstract Number: 405 • 2015 ACR/ARHP Annual Meeting
Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus
Thaschawee Arkachaisri^1,2, Justin Hung Tiong Tan¹, Manasita Tanya¹, Sook Fun Hoh³, Lena Das⁴ and Jing Yao Leong^5,6, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore, ³Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Dept of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁵Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, ⁶SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore
Background/Purpose: Anti-C1q antibodies (AC1q) were shown to strongly correlate with the occurrence and activity of lupus nephritis in adult SLE. Data of the antibodies in…
Abstract Number: 2695 • 2015 ACR/ARHP Annual Meeting
Th17 Cell Related Cytokines and Microarray Expression Profiles in Patients with Early Rheumatoid Arthritis
Youngkyun Kim¹, Kijun Lee², Hae-Rim Kim³, Sang Heon Lee⁴, Ji Hyeon Ju⁵ and HO-YOUN KIM⁶, ¹1Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, South Korea, ²The Catholic University of Korea, Seoul, South Korea, ³Konkuk University Medical Center, Seoul, South Korea, ⁴Konkuk University Hospital, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶Konkuk university hospital, Seoul, South Korea
Background/Purpose: The purpose of this study is to explore new biomarkers for early diagnosis of rheumatoid arthritis (RA). For better discrimination power, we especially investigated…
Abstract Number: 765 • 2015 ACR/ARHP Annual Meeting
Clinical Improvements in Systemic Lupus Erthematosus Are Correlated to Cellular and Soluble Biomarkers in Classical Complement Pathway
Chaim Putterman¹, Jill P. Buyon², Richard Furie³, Rosalind Ramsey-Goldman⁴, Kenneth Kalunian⁵, John Conklin⁶, Tyler O'Malley⁷, Derren Barken⁸ and Thierry Dervieux⁷, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²NYU School of Medicine, New York, NY, ³NSLIJHS, Lake Success, NM, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵UCSD School of Medicine, La Jolla, CA, ⁶1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁷Research and Development, Exagen Diagnostics, Vista, CA, ⁸Exagen Diagnostics, Vista, CA
Background/Purpose : There is a need to identify biomarkers that track disease response in systemic lupus erythematosus (SLE). The value of various biomarkers in monitoring…
Abstract Number: 2917 • 2015 ACR/ARHP Annual Meeting
Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?
Ryota Sakai¹, Akiko Shibata¹, Kentaro Chino¹, Jun Kikuchi², Tsuneo Kondo¹, Ayumi Okuyama¹, Hirofumi Takei¹ and Koichi Amano¹, ¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ²Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Using light microscopy (LM) or immunofluorescence (IF), combined proliferative and membranous lupus nephritis (LN) is defined as an active proliferative class III/IV lesion and…
Abstract Number: 767 • 2015 ACR/ARHP Annual Meeting
Estimating the Pre-Test Probability of Systemic Lupus Erythematosus By Utilizing Anti-Double Stranded DNA and Cell Bound Complement Activation Products Testing from Rheumatology Based Practices in the United States
Stuart L. Silverman¹, Derren Barken², John Conklin³, Claudia Ibarra⁴ and Thierry Dervieux⁵, ¹OMC Clinical Research Center, Beverly Hills, CA, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Clinical Laboratory, Exagen Diagnostics, Vista, CA, ⁵Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose : Clinicians are aware that the interpretation of any clinical diagnostic test and post-test probability of disease is highly influenced by pre-test probability or…
Abstract Number: 2944 • 2015 ACR/ARHP Annual Meeting
Presepsin (sCD14 subtype) Concentration Is Elevated and Reflects Disease Activity in Systemic Lupus Erythematous Patients
Kohei Tsujimoto¹, Masaaki Fujita², Yutaka Shinkawa², Iku Shirasugi¹, Masashi Taniguchi¹, Saori Hatachi³ and Masato Yagita⁴, ¹Department of Clinical Immunology and Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ²Department of Clinical Immunology and Rheumatology C, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ³Department of Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ⁴Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan
Background/Purpose: Presepsin (sCD14 subtype) has recently been identified as a novel biomarker for predicting sepsis. Because presepsin is produced as a consequence of cellular phagocytosis,…
Abstract Number: 776 • 2015 ACR/ARHP Annual Meeting
Sensitivity of Antinuclear Antibody By Immunofluorescence Testing for Detection of Anti-Ro/SSA Antibodies
Ivan Alcantara-Arreola¹, Nina Tello-Winniczuk² and Alejandro Diaz-Borjon³, ¹Hospital Angeles Lomas, Huixquilucan, Mexico, ²Division of Internal Medicine / Rheumatology, Hospital Angeles Lomas, Huixquilucan, Mexico, ³Med/Div of Rheumatology, Hospital Angeles Lomas, Huixquilucan, Mexico
Background/Purpose: A positive ANA test is a diagnostic criterion for several rheumatic diseases, although it may appear in other autoimmune disorders and healthy individuals. An…
Abstract Number: 2961 • 2015 ACR/ARHP Annual Meeting
Reliability and Validity of the Total Joint Count and Swollen Joint Count in Early Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Veronica J. Berrocal², Gandikota Girish³, Meng Zhang⁴, Chris Hatzis¹, Shervin Assassi⁵, Elana J. Bernstein⁶, Robyn T. Domsic⁷, Faye N. Hant⁸, Monique E. Hinchcliff⁹, Elena Schiopu¹⁰, Virginia D. Steen¹¹, Tracy M. Frech¹² and Dinesh Khanna¹³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Radiology, University of Michigan, Ann Arbor, MI, ⁴Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁶Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁷Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Rheumatology, Georgetown University Medical Center, Washington, DC, ¹²Div of Rheumatology, University of Utah, Salt Lake City, UT, ¹³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Arthropathy and tendinopathy in Systemic Sclerosis (SSc) contribute to disability and are associated with disease progression. Clinical trials in SSc sometimes include the tender…
Abstract Number: 777 • 2015 ACR/ARHP Annual Meeting
SLE-KeyTM Rule-out Test to Assess Lupus in Anti-Nuclear Antibody Positive Subjects Using the Immunarray iCHIP®
D. Scott Batty¹, I.R. Cohen², Chaim Putterman³, Nicole Jordan⁴, Keren Jakobi⁵, Rachel Sorek⁵, Yakov Blumenstein⁵, Pennina Safer⁵ and David Pisetsky⁶, ¹ImmunArray Inc., Richmond, VA, ²Weizmann Institute of Science, Rehovot, Israel, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore Medical Center, New York, NY, ⁵ImmunArray LTD, Rehovot, Israel, ⁶Duke University Medical Center and Durham VAMC, Durham, NC
Background/Purpose: SLE is associated with a broad spectrum of autoantibodies, but currently there is no single serologic test to diagnose SLE definitively. Diagnosis is thus…
Abstract Number: 3127 • 2015 ACR/ARHP Annual Meeting
Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®
Chaim Putterman¹, D. Scott Batty², I.R. Cohen³, Nicole Jordan⁴, Debbie Rybak¹, Tamar Rubinstein¹, Keren Jakobi⁵, Rachel Sorek⁵, Anat Reiner-Benaim⁵, Yakov Blumenstein⁵ and Pennina Safer⁵, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²ImmunArray Inc., Richmond, VA, ³Weizmann Institute of Science, Rehovot, Israel, ⁴Montefiore Medical Center, New York, NY, ⁵ImmunArray LTD, Rehovot, Israel
Background/Purpose: Peripheral neurologic syndromes and central nervous system (CNS) manifestations are recognized as primary disease manifestations in systemic lupus erythematosus (SLE). Neuropsychiatric SLE (NPSLE) involves…
Abstract Number: 1095 • 2015 ACR/ARHP Annual Meeting
Identification of Carbamylated Alpha-1-Anti-Trypsin (A1AT) As an Antigenic Target of Anti-Carp Antibodies in Patients with Rheumatoid Arthritis
Marije K. Verheul¹, Alvin Yea², Andrea Seaman², Robert A. Cordfunke³, Jan W. Drijfhout⁴, George M. Janssen⁴, Arnoud de Ru³, Peter A. van Veelen⁴, René E. M. Toes⁵, Michael Mahler² and Leendert A. Trouw¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Inova Diagnostics, San Diego, CA, ³IHB, Leiden University Medical Center, Leiden, Netherlands, ⁴Immunohematology and Bloodbank, Leiden University Medical Center, Leiden, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Antibodies targeting carbamylated proteins (anti-CarP) were recently identified in serum samples from patients with rheumatoid arthritis (RA). The presence of anti-CarP antibodies was associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.